[
    {
        "outcome_uid": "3ac9773e",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: range 6 months to 1 year; assessed with: ACR 20)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "aa711738",
            "834e46fa"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": "Concern about risk of bias associated with lack of allocation concealment and incomplete outcome data in one study is taken into account when rating down for imprecision."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "521/742 (70.2%)",
                    "MTX monotherapy": "188/298 (63.1%)"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.14 (1.03 to 1.26)",
                    "Absolute Effect (95% CI)": "88 more per 1,000 (from 19 more to 164 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "4b8c77ce",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: 6 months; assessed with: ACR 50)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "aa711738",
            "834e46fa"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": "Concern about risk of bias associated with lack of allocation concealment and incomplete outcome data in one study is taken into account when rating down for imprecision."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "426/742 (57.4%)",
                    "MTX monotherapy": "148/298 (49.7%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.17 (1.02 to 1.33)",
                    "Absolute Effect (95% CI)": "84 more per 1,000 (from 10 more to 164 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "41371a37",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: range 6 months to 12 months; assessed with: ACR 70)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "aa711738",
            "834e46fa"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": "Concern about risk of bias associated with lack of allocation concealment and incomplete outcome data in one study is taken into account when rating down for inconsistency."
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=51%."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "378/742 (50.9%)",
                    "MTX monotherapy": "108/298 (36.2%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.36 (1.15 to 1.61)",
                    "Absolute Effect (95% CI)": "130 more per 1,000 (from 54 more to 221 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "4754315d",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disease activity (follow up: range 6 months to 12 months; assessed with: DAS28 or DAS44 (Lower values -> benefit) (values>0.2 are considered clinically important)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=78%."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "TNFi + MTX": "0",
                    "MTX monotherapy": "0"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "SMD 0.21 lower (0.37 lower to 0.05 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "f92893b0",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Remission (follow up: range 6 months to 12 months; assessed with: DAS28<2.6)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "aa711738",
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=58%."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi + MTX": "359/797 (45.0%)",
                    "MTX monotherapy": "116/353 (32.9%)"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.49 (1.25 to 1.77)",
                    "Absolute Effect (95% CI)": "161 more per 1,000 (from 82 more to 253 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "e3789d44",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Radiographic progression (follow up: 1 year; assessed with: mTSS (Lower values \u2013 > benefit) (MCID 4.6)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "0",
                    "MTX monotherapy": "0"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0 (0.64 lower to 0.64 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "c4d70f94",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Fatigue (follow up: 1 year; assessed with: VAS fatigue (Lower values \u2013 > benefit) (MCID -1.12 to -0.82))",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": "Concern about risk of bias associated with lack of allocation concealment taken into account when rating down for imprecision."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi + MTX": "55",
                    "MTX monotherapy": "55"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 5.2 lower (17.17 lower to 6.77 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "e40be137",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Pain (follow up: 1 year; assessed with: VAS pain (Lower values \u2013 > benefit) (MCID -11.9)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": "Concern about risk of bias associated with lack of allocation concealment taken into account when rating down for imprecision."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "55",
                    "MTX monotherapy": "55"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 18.4 lower (30.88 lower to 5.92 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "f060c05d",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Disability (follow up: range 6 months to 12 months; assessed with: HAQ-DI (Lower values \u2013 > benefit) (MCID -0.22)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "aa711738",
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi + MTX": "0",
                    "MTX monotherapy": "0"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.18 lower (0.25 lower to 0.1 lower)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "a5f7c018",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Quality of Life (follow up: range 6 months to 12 months; assessed with: SF-36 PCS (Higher values \u2013 > benefit) (MCID 4.4)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Confidence interval includes both values suggesting no effect and values suggesting benefit. According to the Cochrane's handbook, Cohen suggested that SMD=0.2 be considered a 'small' effect size, 0.5 represents a 'medium' effect size and 0.8 a 'large' effect size. This means that if two groups' means do not differ by 0.2 standard deviations or more, the difference is trivial, even if it is statistically significant."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi + MTX": "0",
                    "MTX monotherapy": "0"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 3.21 higher (0.63 higher to 5.79 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "5ad53f57",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Quality of Life (follow up: range 6 months to 12 months; assessed with: SF-36 MCS (Higher values \u2013 > benefit) (MCID 3.1)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "0",
                    "MTX monotherapy": "0"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "-",
                    "Absolute Effect (95% CI)": "MD 0.54 lower (2.98 lower to 1.89 higher)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "ccbc29f3",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Withdrawal due to lack of efficacy (follow up: range 6 months to 12 months)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "aa711738",
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "MODERATE",
                "No of participants": {
                    "TNFi + MTX": "21/802 (2.6%)",
                    "MTX monotherapy": "24/359 (6.7%)"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.38 (0.21 to 0.69)",
                    "Absolute Effect (95% CI)": "41 fewer per 1,000 (from 53 fewer to 21 fewer)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "2f1f6aff",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Withdrawal due to adverse events (follow up: range 6 months to 12 months)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "aa711738",
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment in 2 studies."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi + MTX": "61/801 (7.6%)",
                    "MTX monotherapy": "24/357 (6.7%)"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.94 (0.60 to 1.49)",
                    "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 27 fewer to 33 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "33249efd",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Serious adverse events (follow up: range 6 months to 12 months)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "aa711738",
            "834e46fa",
            "d354991c"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": "Concern about risk of bias associated with lack of allocation concealment in two studies taken into account when rating down for inconsistency and imprecision."
                },
                "Inconsistency": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious inconsistency. Unexplained heterogeneity I2=72%."
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "VERY LOW",
                "No of participants": {
                    "TNFi + MTX": "91/801 (11.4%)",
                    "MTX monotherapy": "45/357 (12.6%)"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.00 (0.71 to 1.43)",
                    "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 37 fewer to 54 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "9ac37672",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Death (follow up: range 6 months to 12 months)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "aa711738",
            "834e46fa"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious risk of bias. Lack of allocation concealment and incomplete outcome data in one study."
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "SERIOUS",
                    "rationales": "Downgraded by one level due to serious imprecision. Low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "TNFi + MTX": "2/746 (0.3%)",
                    "MTX monotherapy": "1/302 (0.3%)"
                },
                "Annotation": {
                    "data": "1. TNFis include etanercept (ETN), certolizumab (CZP) and adalimumab (ADA).\n"
                },
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.66 (0.06 to 7.23)",
                    "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 3 fewer to 21 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "2aaca0e3",
        "clinical_question": " Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD with MTX or tsDMARD with MTX?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "TNF Inhibitor + MTX",
        "outcome": "Malignancy (from SRs on harms)",
        "related_paper_list": [
            "45b0286b"
        ],
        "assessment_results": {
            "GRADE": {
                "result_interpretation": "The Systematic Review RefID=4638, 2012 (RCTs=3, n=1842) comparing certolizumab + MTX vs placebo + MTX among RA showed that for cancer, the result was RR=2.8 (0.36-21.6) at 1 year and RR=1.3 (0.24-7.3) at all time points. ",
                "Study design": "Systematic Review"
            }
        }
    }
]